SMTI vs. ESTA, FNA, RXST, AORT, PLSE, EYE, AXGN, BVS, EMBC, and CBLL
Should you be buying Sanara MedTech stock or one of its competitors? The main competitors of Sanara MedTech include Establishment Labs (ESTA), Paragon 28 (FNA), RxSight (RXST), Artivion (AORT), Pulse Biosciences (PLSE), National Vision (EYE), AxoGen (AXGN), Bioventus (BVS), Embecta (EMBC), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry.
Sanara MedTech vs.
Sanara MedTech (NASDAQ:SMTI) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
Sanara MedTech has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
Establishment Labs received 98 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 62.30% of users gave Establishment Labs an outperform vote while only 58.33% of users gave Sanara MedTech an outperform vote.
In the previous week, Sanara MedTech and Sanara MedTech both had 7 articles in the media. Establishment Labs' average media sentiment score of 0.87 beat Sanara MedTech's score of 0.00 indicating that Establishment Labs is being referred to more favorably in the news media.
8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 54.1% of Sanara MedTech shares are owned by company insiders. Comparatively, 11.4% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Sanara MedTech currently has a consensus target price of $47.00, indicating a potential upside of 50.64%. Establishment Labs has a consensus target price of $57.40, indicating a potential upside of 38.11%. Given Sanara MedTech's stronger consensus rating and higher possible upside, equities analysts plainly believe Sanara MedTech is more favorable than Establishment Labs.
Sanara MedTech has higher earnings, but lower revenue than Establishment Labs. Sanara MedTech is trading at a lower price-to-earnings ratio than Establishment Labs, indicating that it is currently the more affordable of the two stocks.
Sanara MedTech has a net margin of -10.71% compared to Establishment Labs' net margin of -46.13%. Sanara MedTech's return on equity of -19.86% beat Establishment Labs' return on equity.
Summary
Sanara MedTech beats Establishment Labs on 9 of the 17 factors compared between the two stocks.
Get Sanara MedTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMTI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sanara MedTech Competitors List
Related Companies and Tools
This page (NASDAQ:SMTI) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy SMTI Stock Free SMTI Stock Alerts